passive immunotherapy


Also found in: Dictionary, Thesaurus, Medical.
Related to passive immunotherapy: active immunotherapy

passive immunotherapy

[¦pas·iv ‚im·yə′ther·ə·pē]
(immunology)
Immunotherapy involving the transfer of antibodies to tumor-bearing recipients.
Mentioned in ?
References in periodicals archive ?
Some of the most impressive results using passive immunotherapy were recently reported by Steven A.
Chain's seminal discovery in 1997, which laid the foundations for Alzheimer's passive immunotherapy treatments targeting the soluble beta amyloid that accumulates in the brain of Alzheimer's patients leading to neurodegeneration.
To determine whether a clinical rationale exists for attempting passive immunotherapy for HCPS with neutralizing antibodies, we first studied the relationship between the titer of such antibodies on a patients' admission to the hospital and the clinical outcome.
The new ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs.
Both the active and passive immunotherapy is directed against the beta amyloid protein which misfolds and forms plaques in Alzheimer's disease.
Passive immunotherapy with monoclonal therapeutic antibodies against Staphylococcus aureus is another means to approach specific therapy of staphylococcal.
The strategy to develop active immunotherapies complements our current passive immunotherapy platform based on GBP-102, our Anti-CD55+ therapeutic antibody candidate," stated Mr.
Whatever functional defect these immune cells have likely impacts the effectiveness of both active immunotherapy, like cancer vaccines, and passive immunotherapy, like cellular therapies," said Lee.
In passive immunotherapy, monoclonal antibodies are directed against beta amyloid facilitating removal of beta amyloid and thus reducing its accumulation in the brain.
Third quarter 2008 passive immunotherapy product and byproduct sales were $10.
The report provides detailed tables from the key presentations at ICAD, as well as discussion of key compounds in development, including acetylcholinesterase inhibitors, NMDA, serotonin (5HT), alpha-7 nicotinic acetylcholine agonists, active and passive immunotherapy, gamma-secretase and beta-secretase inhibitors, insulin related mechanisms (IDE, RAGE), mitochondrial stabilization, metal chelation, and more.

Full browser ?